Navigation Links
IBS Sufferers Benefited by Non-Absorbable Antibiotics

A non absorbable antibiotic which stays in the gut has been found to be an effective long-term treatment for irritable// bowel syndrome (IBS) according to researchers at Cedars-Sinai Medical Center.

The study has been published in the October 17 issue of the Annals of Internal Medicine It is the first to demonstrate benefits from antibiotic use even after end of the course of treatment has ended. This study has supported previously published research that identified small intestine bacterial overgrowth as a cause of the disease.

This study was a randomized, double-blind, placebo-controlled study involving 87 participants, all of whom met specific multinational guidelines for diagnosis of IBS. They received 400 mg of the antibiotic rifaximin three times a day for 10 days or a placebo.

The participants were required to complete an extensive symptom questionnaire at the start of the study and then weekly for 10 weeks following treatment. The questionnaire measured the severity of nine symptoms (abdominal pain, constipation, diarrhea, urgency, bloating, sense of incomplete evacuation, incomplete evacuation, mucus, and gas). Patients were also asked to provide a% global improvement from 0 to 100% in their overall IBS symptoms.

The study revealed that rifaximin not only led to significant improvement in global IBS symptoms during the 10 days it was administered, but showed a continuance of the benefit continued for the 10 weeks of follow up when no antibiotic was given, showing sustained benefit.

Mark Pimentel, M.D., director of the GI Motility Program at Cedars-Sinai and the study's principal investigator said, "The fact that the benefit of the targeted antibiotic continued even after it was stopped provides evidence that the antibiotic was acting on a source of the problem: excess bacteria in the gut. This finding offers a new treatment approach -- and a new hope -- for people with IBS."

Irritable Bowe l Syndrome affects about 20% of Americans and is one of the top 10 most frequently diagnosed conditions by U.S. physicians. The disorder is characterized by abdominal pain, cramping, bloating and diarrhea and/or constipation and is a long-term condition that usually begins in early adult life. The episodes may be mild or severe and may be exacerbated by stress and is more common in women than in men.

Pimentel said, "While this study being released today demonstrates that the non-absorbed antibiotic rifaximin has great promise in the clinical improvement of IBS, more research is needed. Next steps include multi-center studies to further assess short- and long-term benefits of this drug. Tests comparing rifaximin to other types of antibiotics that have been used to treat the disease should also be conducted."

Treatments for this disease have been mainly focused on reducing its symptoms because researchers are still clueless about its cause. In the Dec 2000 issue of American Journal of Gastroenterology, Pimentel linked bloating, the most common symptom of IBS, to bacterial fermentation by giving lactulose breath tests to participants.

This test monitors the level of hydrogen and methane on the breath and showed evidence that small intestine bacteria overgrowth may be a causative factor in IBS. The current Annals study participants also took the breath tests, which showed similarly increased levels of hydrogen and methane.

Rifaximin is manufactured by Salix Pharmaceuticals, Inc. Funding for the study was also provided by Salix. The discovery related to the use of rifaximin for IBS was made at Cedars-Sinai by Pimentel. Cedars-Sinai holds patent rights to this discovery and has licensed rights to the invention to Salix.
NLA
'"/>




Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Do Asthma Sufferers Lack Physical Activity?
3. Asthma Sufferers Lacking Physical Activity
4. Hope for Dust Mite Allergy Sufferers
5. Promise for Soya Allergy Sufferers
6. AIDS Sufferers Protest against Proposed Patent for Tenofovir
7. Zambia Struggling To Identify AIDS Sufferers
8. Celiac Disease Sufferers See an End to their Misery
9. AIDS Sufferers Turn to British Doctor to Prolong their Survival
10. Exercise DVD Available For COPD Sufferers
11. Sleep Apnea Sufferers-Viagra May Make The Condition Worse
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: